May 5, 2026 | Pharma, healthcare, patient access
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

Inizio announced the official launch of its fully integrated, end-to-end Hub Services, a cornerstone of its market-leading Patient Solutions offering. Delivered by Inizio Engage, the Inizio business unit specializing in patient engagement and support, this next-generation solution addresses the growing complexity of patient access, reimbursement, and adherence, while enabling clients to partner with a more agile, strategic, and outcome-driven organization.
As life sciences organizations navigate an increasingly dynamic policy and payer landscape, and higher expectations from patients, the need for more connected, patient-centric support models has never been greater. “Inizio Engage’s evolved Hub Services introduces a next-generation approach, integrating human expertise, intelligent technology, and pharmacy capabilities, supported by advanced analytics to simplify and accelerate the path to therapy,” said Ryan Quigley, CEO, Inizio. “This launch represents another opportunity for Inizio to lead the way as the global Intelligent Commercialization partner, bringing together insight, innovation, and execution to deliver more coordinated, patient-centered solutions for our clients.”
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on…
An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at…
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only…
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Five new recruits support further growth of the Pharma & Life Sciences team
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we’ve been using facial analysis to delve further into respondents’ reactions…
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU & Japan) 2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in…
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1…
Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges…
In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,…
